FY2024 EPS Forecast for Stoke Therapeutics Lifted by Analyst

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities researchers at Wedbush boosted their FY2024 earnings estimates for shares of Stoke Therapeutics in a note issued to investors on Tuesday, November 5th. Wedbush analyst L. Chico now expects that the company will post earnings per share of ($2.00) for the year, up from their previous forecast of ($2.03). The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.10) per share. Wedbush also issued estimates for Stoke Therapeutics’ Q3 2025 earnings at ($0.62) EPS, FY2025 earnings at ($2.40) EPS, FY2026 earnings at ($2.51) EPS, FY2027 earnings at ($2.05) EPS and FY2028 earnings at ($0.76) EPS.

A number of other research analysts also recently weighed in on the company. Needham & Company LLC restated a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research note on Wednesday. HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a report on Wednesday. Leerink Partners initiated coverage on shares of Stoke Therapeutics in a report on Monday, October 14th. They set an “outperform” rating and a $18.00 target price on the stock. Finally, Leerink Partnrs raised shares of Stoke Therapeutics to a “strong-buy” rating in a research report on Friday, October 11th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $20.83.

Stoke Therapeutics Stock Up 4.6 %

Shares of STOK opened at $13.88 on Friday. Stoke Therapeutics has a twelve month low of $3.77 and a twelve month high of $17.58. The stock has a market capitalization of $735.22 million, a P/E ratio of -6.61 and a beta of 0.95. The company has a 50 day moving average of $13.21 and a 200-day moving average of $13.72.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. The business had revenue of $4.89 million for the quarter, compared to analyst estimates of $3.46 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 1,937,500 shares of the stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the sale, the insider now directly owns 8,906,181 shares in the company, valued at $125,131,843.05. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 11.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Redmile Group LLC boosted its holdings in shares of Stoke Therapeutics by 93.2% during the 1st quarter. Redmile Group LLC now owns 5,073,049 shares of the company’s stock valued at $68,486,000 after acquiring an additional 2,447,543 shares in the last quarter. Lynx1 Capital Management LP boosted its stake in shares of Stoke Therapeutics by 40.3% during the second quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock valued at $70,052,000 after purchasing an additional 1,488,371 shares in the last quarter. Assenagon Asset Management S.A. bought a new stake in shares of Stoke Therapeutics during the second quarter worth about $19,835,000. Baker BROS. Advisors LP increased its stake in shares of Stoke Therapeutics by 65.9% in the first quarter. Baker BROS. Advisors LP now owns 3,368,443 shares of the company’s stock valued at $45,474,000 after buying an additional 1,338,309 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund raised its holdings in Stoke Therapeutics by 426.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock valued at $18,741,000 after buying an additional 1,123,500 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.